MetaCap

Alector (ALEC) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alector (ALEC) has outperformed Tevogen (TVGN) over the past year, gaining 88.3% versus a loss of 73.8%. Tevogen is the larger company by market cap ($405.2 million vs $347.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALEC+88.31%TVGN-73.84%
+129%+18%-93%
Nov 21, 20251 yearNov 20, 2026
ALEC-86.96%TVGN-98.81%
+20%-43%-105%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALEC versus TVGN key metrics
MetricALECTVGN
Share price$2.34$5.90
Market cap$347.63M$405.20M
1-day change+1.52%-6.35%
YTD return+49.68%-64.35%
1-year return+88.31%-73.84%
5-year return-88.28%—
P/E ratio (TTM)6.31—
EPS (TTM)$0.37$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.05M—
Revenue growth (YoY)-79.07%—
Net income (latest FY)$-142.93M$-26.28M
Operating margin-741.30%—
Net margin-679.16%—
52-week high$2.84$24.90
52-week low$1.09$3.64
Distance from 52-week high-17.78%-76.31%
Analyst consensusbuy—
Avg. price target upside+89.29%—
Average volume3.34M7.94K
Shares outstanding148.88M68.68M
Employees10318
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALEC has outperformed TVGN by 162.1 percentage points over the past year.

About Alector

ALEC stock →

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

ALEC vs TVGN FAQ

Which is bigger, Alector or Tevogen?

Tevogen (TVGN) is larger, with a market capitalization of $405.20M compared with $347.63M for Alector (ALEC).

Which stock has performed better over the past year, ALEC or TVGN?

ALEC returned +88.31% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are Alector and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons